Profile data is unavailable for this security.
About the company
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
- Revenue in USD (TTM)3.50m
- Net income in USD-54.19m
- Incorporated1989
- Employees84.00
- LocationAbeona Therapeutics Inc6555 CARNEGIE AVE, 4TH FLOORCLEVELAND 44103United StatesUSA
- Phone+1 (646) 813-4701
- Fax+1 (302) 655-5049
- Websitehttps://abeonatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -37.94m | 195.45m | 42.00 | -- | 15.20 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -29.16m | 196.47m | 121.00 | -- | 2.33 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
| Capricor Therapeutics Inc | 25.18m | -22.29m | 196.89m | 101.00 | -- | 8.61 | -- | 7.82 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Werewolf Therapeutics Inc | 19.94m | -37.37m | 200.44m | 47.00 | -- | 1.65 | -- | 10.05 | -1.05 | -1.05 | 0.5595 | 2.85 | 0.119 | -- | 4.82 | 424,319.20 | -22.30 | -- | -25.62 | -- | -- | -- | -187.37 | -- | -- | -- | 0.2609 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.94m | 201.07m | 3.00 | -- | 22.71 | -- | -- | -0.7024 | -0.7024 | 0.00 | 0.689 | 0.00 | -- | -- | 0.00 | -72.07 | -30.86 | -73.66 | -32.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.21 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 201.36m | 25.00 | -- | 2.42 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Codexis Inc | 70.14m | -76.24m | 201.77m | 174.00 | -- | 2.32 | -- | 2.88 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Gossamer Bio Inc | 0.00 | -179.82m | 201.94m | 135.00 | -- | 3.21 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 206.53m | 84.00 | -- | 13.51 | -- | 59.01 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 208.00m | 10.00 | -- | 2.29 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 208.45m | 65.00 | -- | 3.22 | -- | 7.59 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Design Therapeutics Inc | 0.00 | -66.86m | 208.46m | 58.00 | -- | 0.7504 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| bluebird bio Inc | 21.73m | -91.17m | 209.39m | 323.00 | -- | 0.529 | -- | 9.64 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 210.45m | 147.00 | -- | -- | -- | 1.80 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 213.33m | -- | -- | 11.24 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
Data as of Apr 15 2024. Currency figures normalised to Abeona Therapeutics Inc's reporting currency: US Dollar USD
43.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2023 | 3.25m | 11.88% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 2.25m | 8.23% |
| Millennium Management LLCas of 31 Dec 2023 | 1.42m | 5.19% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.09m | 3.99% |
| Western Standard LLCas of 31 Dec 2023 | 808.11k | 2.95% |
| AIGH Capital Management LLCas of 31 Dec 2023 | 787.77k | 2.88% |
| Point72 Asset Management LPas of 31 Dec 2023 | 760.87k | 2.78% |
| Ikarian Capital LLCas of 31 Dec 2023 | 600.00k | 2.19% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2023 | 450.35k | 1.65% |
| J. Goldman & Co. LPas of 31 Dec 2023 | 429.82k | 1.57% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
